skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 
Home » Regular Columns » Three Quick Facts » Three Quick Facts: GlaxoSmithKline, Pearson and Tekcapital

Here are three things you need to know in the financial markets this morning from investment writer, Tony Cross.

#1. GlaxoSmithKline new product accepted for FDA review

Perhaps unsurprisingly pickings are rather slim off the back of the holiday weekend, but GlaxoSmithKline [LON:GSK] has advised that a new product for the treatment of chronic kidney disease has been submitted to the FDA for phase three testing. The product is already approved in Japan but as always tapping into the lucrative US market is a key milestone for any drug.

#2.  Pearson US contract to conclude

Educational publisher Pearson [LON:PSON] has this morning advised that its 10 year association with Arizona State University will conclude in 2023. Whilst the partnership is said to have been ground breaking in terms of allowing ASU to expand online learning, the profit impact is set to be modest during termination and subsequently will be offset by the elimination of related costs. Earnings guidance for the short to medium term remains unchanged.

#3. Tekcapital portfolio company update

Rounding off with an AIM market company, Tekcapital [LON:TEK] has this morning reported that wholly owned portfolio company Guidant it has executed a strategic alliance with Perrone Robotics. This sees Guident’s remote monitoring systems integrated with Perrone’s kit for highly automated vehicles and has the potential to accelerate the adoption of autonomous vehicles in cities. The Autonomous vehicle market is tipped to be worth $556 billion by 2026.


Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

Tony Cross

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.


Subscribe for more stories like this, 8am weekdays - for free!

Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Back To Top